Table 2.

Effects of gemcitabine and gemcitabine-bortezomib combinations on NTP levels H460 and SW1573 NSCLC cells (pmol/106 cells)

CellsControl*Treatments
Gemcitabine (4 h)Gemcitabine (4 + 4 h retention)Gemcitabine + bortezomib (4 h)Gemcitabine + bortezomib (4 + 4 h)Bortezomib (2 h)- gemcitabine (4 h)Bortezomib (2 h)- gemcitabine (4 + 4 h)
ATPH4601,136 ± 27311717298124142206
SW15732,299 ± 557114126117105134207
GTPH460251 ± 65112176101129130228
SW1573643 ± 1628299102101111124
UTPH460463 ± 151127193114149150258
SW15731,511 ± 47678958789100154
CTPH460202 ± 57160301135237215348
SW1573319 ± 34157166170195207293
  • *Control values (mean ± SE; pmol/106 cells) from three independent experiments.

  • Percentages with respect to control values.

  • P < 0.05, significantly different from untreated cells.